-
Sonnet BioTherapeutics :SONN Sonnet’s proprietary FHAB™ (Fully Human Albumin Binding) technology enables the development of innovative targeted biologic drugs with enhanced single- or bi-specific mechanisms. The FHAB™ platform utilizes a fully human single chain antibody fragment (scFv) that binds to and “hitchhikes” on human serum albumin (HSA) for transport to target tissues. Our internal focus is immune oncology, however, we believe our technology is suited for drug development across the spectrum of human disease.
Location: | Industry: | Sector:
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-335.9K
Cash
4.862M
Avg Qtr Burn
-2.107M
Short % of Float
3.84%
Insider Ownership
1.57%
Institutional Own.
3.06%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
SON-080 Details Chemotherapy-Induced Peripheral Neuropathy | Phase 2 Initiation | |
SON-1010 (IL12-FHAB) Details Solid tumor/s, Cancer, Ovarian cancer, Platinum-resistant ovarian cancer | Phase 1/2 Data readout | |
SON-1210 w/chemotherapeutic agents Details Cancer, Pancreatic cancer | Phase 1/2 Initiation | |
SON-1010 (IL12-FHAB) +/- Trabectedin Details Cancer, Solid tumor/s | Phase 1 Data readout |